Association of hyperglycaemia and hyperlipidaemia with cognitive dysfunction in schizophrenia spectrum disorder

References

• Bora, E., 2015. Neurodevelopmental origin of cognitive impairment in schizophrenia. Psychological medicine, 45 (1), 1–9.
   PubMed Web of Science ®Google Scholar
• Chang, W.C., et al., 2019. Abnormal cognitive effort allocation and its association with amotivation in first-episode psychosis. Psychological medicine, 1, 1–11.
   Google Scholar
• Cohen, D., et al., 2006. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes care, 29 (4), 786–791.
   PubMed Web of Science ®Google Scholar
• Devanarayanan, S., et al., 2016. Elevated copper, hs C-reactive protein and dyslipidemia in drug free schizophrenia: relation with psychopathology score. Asian journal of psychiatry, 24, 99–102.
   PubMed Web of Science ®Google Scholar
• Dwyer, D.S., et al., 2001. Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 13 (2), 103–113.
   PubMedGoogle Scholar
• Giles, G.E., et al., 2018. Sugar intake and expectation effects on cognition and mood. Experimental and clinical psychopharmacology, 26 (3), 302–309.
   PubMed Web of Science ®Google Scholar
• Gispen, W.H. and Biessels, G.J., 2000. Cognition and synaptic plasticity in diabetes mellittus. Trends in neurosciences, 23 (11), 542–549.
   PubMed Web of Science ®Google Scholar
• Guest, P.C., 2019. Insulin resistance in schizophrenia. Advances in experimental medicine and biology, 1134, 1–16.
   PubMed Web of Science ®Google Scholar
• Hsu, J.H., Chien, I.C., and Lin, C.H., 2015. Increased risk of hyperlipidemia in patients with bipolar disorder: a population-based study. General hospital psychiatry, 37 (4), 294–298.
   PubMed Web of Science ®Google Scholar
• Jimenez, M.A. and Guerrero, J.L.G., 2017. Disorders associated with mild cognitive impairment. Risk factors and predictors. Revista espanola de geriatria y gerontologia, 52, 20–23.
   Google Scholar
• Kay, S.R., Fiszbein, A., and Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia bulletin, 13 (2), 261–276.
   PubMed Web of Science ®Google Scholar
• Knopfholz, J., et al., 2014. Validation of the friedewald formula in patients with metabolic syndrome. Cholesterol, 2014, 1–5.
   Google Scholar
• Krug, A. and Kircher, T., 2017. Cognitive disorders in schizophrenia. Fortschritte der neurologie-psychiatrie, 85 (5), 292–304.
   PubMed Web of Science ®Google Scholar
• Li, G., et al., 2005. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology, 65 (7), 1045–1050.
   PubMed Web of Science ®Google Scholar
• Ma, C., et al., 2017. Blood cholesterol in late-life and cognitive decline: a longitudinal study of the Chinese elderly. Molecular neurodegeneration, 12, 24.
   PubMed Web of Science ®Google Scholar
• Mauch, D.H., et al., 2001. CNS synaptogenesis promoted by glia-derived cholesterol. Science (New York, N.Y., 294 (5545), 1354–1357.
   Google Scholar
• Moheet, A., Mangia, S., and Seaquist, E.R., 2015. Impact of diabetes on cognitive function and brain structure. Annals of the New York Academy of Sciences, 1353, 60–71.
   PubMed Web of Science ®Google Scholar
• Newcomer, J.W., 2005. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS drugs, 19 (Supplement 1), 1–93.
   PubMedGoogle Scholar
• Nilsson, A., Radeborg, K., and Björck, I., 2012. Effects on cognitive performance of modulating the postprandial blood glucose profile at breakfast. European journal of clinical nutrition, 66 (9), 1039–1043.
   PubMed Web of Science ®Google Scholar
• Panza, F., et al., 2011. Metabolic syndrome, mild cognitive impairment, and dementia. Current Alzheimer research, 8 (5), 492–509.
   PubMed Web of Science ®Google Scholar
• Peixoto, B., et al., 2018. Validation of the Portuguese version of Addenbrooke’s cognitive examination III in mild cognitive impairment and dementia. Advances in clinical and experimental medicine, 27 (6), 781–786.
   PubMed Web of Science ®Google Scholar
• Reitz, C., 2013. Dyslipidemia and the risk of Alzheimer’s disease. Current atherosclerosis reports, 15 (3), 307.
   PubMed Web of Science ®Google Scholar
• Sagar, R., et al., 2020. The burden of the mental disorders across the state of India: the global burden of disease study 1990-2017. The Lancet psychiatry, 7 (2), 148–161.
   PubMed Web of Science ®Google Scholar
• Smucny, J., et al., 2020. One-year stability of frontoparietal cognitive control network connectivity in recent onset schizophrenia: a task-related 3T fMRI study. Schizophrenia bulletin, 46 (5), 1249–1258.
   PubMed Web of Science ®Google Scholar
• Sunram-Lea, S.I. and Owen, L., 2017. The impact of diet-based glycaemic response and glucose regulation on cognition: evidence across the lifespan. The proceedings of the Nutrition Society, 76 (4), 466–477.
   PubMed Web of Science ®Google Scholar
• Thakur, J.H., 2004. Metabolic disturbance in first-episode schizophrenia. British journal of psychiatry, 47, S76–S79.
   Google Scholar
• Umegaki, H., 2012. Neurodegeneration in diabetes mellitus. Advances in experimental medicine and biology, 724, 258–265.
   PubMed Web of Science ®Google Scholar
• van Vliet, I.M. and de Beurs, E., 2007. The MINI-International Neuropsychiatric Interview. A brief structured diagnostic psychiatric interview for DSM-IV en ICD-10 psychiatric disorders. Tijdschrift Voor Psychiatrie, 49 (6), 393–397.
   PubMedGoogle Scholar
• Vivanco-Hidalgo, R.M., et al., 2017. Prevalence of cardiovascular risk factors in people with epilepsy. Brain and behavior, 7 (2), e00618.
   PubMed Web of Science ®Google Scholar
• Wu, X., et al., 2013. The comparison of glycometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls. Schizophrenia research, 150 (1), 157–162.
   PubMed Web of Science ®Google Scholar
• Yaffe, K., et al., 2002. Serum lipoprotein levels, statin use, and cognitive function in older women. Archives of neurology, 59 (3), 378–384.
   PubMedGoogle Scholar
• Zhang, X.Y., et al., 2015. Glucose disturbances in first-episode drug-naïve schizophrenia: relationship to psychopathology. Psychoneuroendocrinology, 62, 376–380.
   PubMed Web of Science ®Google Scholar